These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

382 related items for PubMed ID: 10773226

  • 21. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ, Zhang X, Zhu WL, Huang Y.
    Zhonghua Yi Xue Za Zhi; 2006 Jun 27; 86(24):1693-6. PubMed ID: 16854324
    [Abstract] [Full Text] [Related]

  • 22. Association of matrix metalloproteinase expression and left ventricular function in idiopathic dilated cardiomyopathy.
    Yokoseki O, Yazaki Y, Suzuki J, Imamura H, Takenaka H, Isobe M.
    Jpn Circ J; 2000 May 27; 64(5):352-7. PubMed ID: 10834450
    [Abstract] [Full Text] [Related]

  • 23. Matrix metalloproteinase inhibition and the prevention of heart failure.
    Lee RT.
    Trends Cardiovasc Med; 2001 Jul 27; 11(5):202-5. PubMed ID: 11597832
    [Abstract] [Full Text] [Related]

  • 24. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat.
    Peterson JT, Li H, Dillon L, Bryant JW.
    Cardiovasc Res; 2000 May 27; 46(2):307-15. PubMed ID: 10773235
    [Abstract] [Full Text] [Related]

  • 25. Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: a marker of cardiac dilatation.
    Reddy HK, Tjahja IE, Campbell SE, Janicki JS, Hayden MR, Tyagi SC.
    Mol Cell Biochem; 2004 Sep 27; 264(1-2):183-91. PubMed ID: 15544047
    [Abstract] [Full Text] [Related]

  • 26. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure.
    Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG.
    Circulation; 2001 May 08; 103(18):2303-9. PubMed ID: 11342481
    [Abstract] [Full Text] [Related]

  • 27. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
    Kandalam V, Basu R, Abraham T, Wang X, Soloway PD, Jaworski DM, Oudit GY, Kassiri Z.
    Circ Res; 2010 Mar 05; 106(4):796-808. PubMed ID: 20056917
    [Abstract] [Full Text] [Related]

  • 28. Membrane-type-1 matrix metalloproteinase transcription and translation in myocardial fibroblasts from patients with normal left ventricular function and from patients with cardiomyopathy.
    Spruill LS, Lowry AS, Stroud RE, Squires CE, Mains IM, Flack EC, Beck C, Ikonomidis JS, Crumbley AJ, McDermott PJ, Spinale FG.
    Am J Physiol Cell Physiol; 2007 Oct 05; 293(4):C1362-73. PubMed ID: 17670887
    [Abstract] [Full Text] [Related]

  • 29. Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy.
    Sivakumar P, Gupta S, Sarkar S, Sen S.
    Mol Cell Biochem; 2008 Jan 05; 307(1-2):159-67. PubMed ID: 17849172
    [Abstract] [Full Text] [Related]

  • 30. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.
    Hsu CP, Huang CY, Wang JS, Sun PC, Shih CC.
    Ann Thorac Surg; 2008 Oct 05; 86(4):1243-9. PubMed ID: 18805169
    [Abstract] [Full Text] [Related]

  • 31. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3.
    Fedak PW, Altamentova SM, Weisel RD, Nili N, Ohno N, Verma S, Lee TY, Kiani C, Mickle DA, Strauss BH, Li RK.
    Am J Physiol Heart Circ Physiol; 2003 Feb 05; 284(2):H626-34. PubMed ID: 12388270
    [Abstract] [Full Text] [Related]

  • 32. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.
    Spinale FG.
    Physiol Rev; 2007 Oct 05; 87(4):1285-342. PubMed ID: 17928585
    [Abstract] [Full Text] [Related]

  • 33. MMP induction and inhibition in myocardial infarction.
    Lindsey ML.
    Heart Fail Rev; 2004 Jan 05; 9(1):7-19. PubMed ID: 14739764
    [Abstract] [Full Text] [Related]

  • 34. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.
    Peterson JT.
    Heart Fail Rev; 2004 Jan 05; 9(1):63-79. PubMed ID: 14739769
    [Abstract] [Full Text] [Related]

  • 35. Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts.
    Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ.
    Mol Cell Biochem; 1996 Feb 09; 155(1):13-21. PubMed ID: 8717434
    [Abstract] [Full Text] [Related]

  • 36. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice.
    Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK, Edwards DR, Liu PP, Backx PH, Khokha R.
    Circ Res; 2005 Aug 19; 97(4):380-90. PubMed ID: 16037568
    [Abstract] [Full Text] [Related]

  • 37. Loss of PI3Kγ enhances cAMP-dependent MMP remodeling of the myocardial N-cadherin adhesion complexes and extracellular matrix in response to early biomechanical stress.
    Guo D, Kassiri Z, Basu R, Chow FL, Kandalam V, Damilano F, Liang W, Izumo S, Hirsch E, Penninger JM, Backx PH, Oudit GY.
    Circ Res; 2010 Nov 12; 107(10):1275-89. PubMed ID: 20847309
    [Abstract] [Full Text] [Related]

  • 38. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness.
    Klotz S, Foronjy RF, Dickstein ML, Gu A, Garrelds IM, Danser AH, Oz MC, D'Armiento J, Burkhoff D.
    Circulation; 2005 Jul 19; 112(3):364-74. PubMed ID: 15998679
    [Abstract] [Full Text] [Related]

  • 39. Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload.
    Zile MR, Baicu CF, Stroud RE, Van Laer AO, Jones JA, Patel R, Mukherjee R, Spinale FG.
    Circ Heart Fail; 2014 Mar 01; 7(2):340-50. PubMed ID: 24395927
    [Abstract] [Full Text] [Related]

  • 40. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
    Li YY, Feldman AM.
    Drugs; 2001 Mar 01; 61(9):1239-52. PubMed ID: 11511020
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.